ERBB2 and neoplasm: However, androgen receptors are found in 80 to 90% of SDC, as well as 30 to 70% expressing the human epidermal growth factor receptor (EGFR) and Her2neu, making the tumor a target for androgen deprivation therapy and monoclonal antibodies like cetuximab or trastuzumab, respectively (14, 40, 57–61).